EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database

Changsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, Lori Wood iD, Georg A Bjarnason iD, Bimal Bhindi, Daniel Yick Chin Heng, Vincent Castonguay, Frederic Pouliot iD, Christian K Kollmannsberger, Dominick Bosse iD, Naveen S Basappa und 7 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31080351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Changsu Lawrence Park und 18 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nephrectomy, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kidney Cancer Research Network of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immunotherapy. The primary objective of this study is to assess outcomes in patients who received ST only, CN followed by ST (CN-ST), and ST followed by CN (ST-CN). The Canadian Kidney Cancer information system (CKCis) database was queried to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023. These patients were classified into three categories as described above. Cox proportional hazards models were used to assess the impact of the timing of ST and CN on overall survival (OS) and progression-free survival (PFS), after adjusting for the International Metastatic RCC Database Consortium (IMDC) risk group, age, and comorbidities. Best overall response and complications of ST and CN for these cohorts were collected. A total of 588 patients were included in this study: 331 patients received ST only, 215 patients received CN-ST, and 42 patients received ST-CN. Patient and disease characteristics including age, gender, performance status, IMDC risk category, comorbidity, histology, type of ST, and metastatic sites are reported. OS analysis favored patients who received ST-CN (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.13–0.68) and CN-ST (HR 0.68, CI 0.47–0.97) over patients who received ST only. PFS analysis showed a similar trend for ST-CN (HR 0.45, CI 0.26–0.77) and CN-ST (HR 0.9, CI 0.68–1.17). This study examined baseline features and outcomes associated with the use and timing of CN and ST using real-world data via a large Canadian real-world cohort. Patients selected to receive CN after ST demonstrated improved outcomes. There were no appreciable differences in perioperative complications across groups. Limitations include the small number of patients in the ST-CN group and residual confounding and selection biases that may influence the outcomes in patients undergoing CN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellNephrectomyKidney NeoplasmsImmunotherapyCytoreduction Surgical ProceduresHumansMaleFemaleMiddle AgedAgedDatabases, FactualCanadaTreatment Outcome

Stichwörter der Autor:innen

CKCiscytoreductive nephrectomyimmunotherapyreal-world datarenal cell carcinoma

Autor:innen und Institutionen

  • McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.
  • Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
  • Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 3A7, Canada.
  • Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada.
  • Southern Alberta Institute of Urology, Calgary, AB T2V 1P9, Canada.
  • Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada.

ORCID-Profile: Lori Wood, Georg A Bjarnason, Frederic Pouliot, Dominick Bosse, Aly-Khan A Lalani, Ramy R Saleh

Förderung

  • Kidney Cancer Research Network of Canada

Zitieren

APA

Park, C. L., Moria, F. A., Ghosh, S., Wood, L., Bjarnason, G. A., Bhindi, B., Heng, D. Y. C., Castonguay, V., Pouliot, F., Kollmannsberger, C. K., Bosse, D., Basappa, N. S., Finelli, A., Fallah-Rad, N., Breau, R. H., Lalani, A. A., Tanguay, S., Graham, J., & Saleh, R. R. (2024). Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database. Current Oncology. https://doi.org/10.3390/curroncol31080351

Vancouver

Park CL, Moria FA, Ghosh S, Wood L, Bjarnason GA, Bhindi B, et al. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database. Current Oncology. 2024. doi:10.3390/curroncol31080351

BibTeX
@article{Park2024,
  author = {Park, Changsu Lawrence and Moria, Feras Ayman and Ghosh, Sunita and Wood, Lori and Bjarnason, Georg A and Bhindi, Bimal and Heng, Daniel Yick Chin and Castonguay, Vincent and Pouliot, Frederic and Kollmannsberger, Christian K and Bosse, Dominick and Basappa, Naveen S and Finelli, Antonio and Fallah-Rad, Nazanin and Breau, Rodney H and Lalani, Aly-Khan A and Tanguay, Simon and Graham, Jeffrey and Saleh, Ramy R},
  title = {Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31080351}
}
Kostenlos starten →